LakeShore Biopharma (YSBPW) appoints advisors to its special committee

Rhea-AI Filing Summary

LakeShore Biopharma Co., Ltd. submitted a foreign issuer report describing a recent corporate governance step. The company furnished a press release as an exhibit stating that it has appointed an independent financial advisor and legal counsel to its special committee. The report is signed by Director and Chief Financial Officer Rachel Yu.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission file number: 001-41598

LAKESHORE BIOPHARMA CO., LTD

(Exact name of registrant as specified in its charter)

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒          Form 40-F  ☐

EXHIBITS

Exhibit No.		Description
99.1		Press Release - LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

1

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LakeShore Biopharma Co., Ltd
	By:	/s/ Rachel Yu
	Name:	Rachel Yu
	Title:	Director and Chief Financial Officer

Date: September 10, 2025

2

FAQ

What does LakeShore Biopharma Co., Ltd. (YSBPW) report in this Form 6-K?

LakeShore Biopharma reports that it furnished a press release announcing the appointment of an independent financial advisor and legal counsel to its special committee, reflecting an additional layer of external expertise supporting the committee’s work.

What exhibit is included with LakeShore Biopharma’s (YSBPW) September 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, a press release titled “LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee,” which formally documents these new advisory appointments for investors and regulators.

Who signed LakeShore Biopharma’s (YSBPW) September 2025 Form 6-K?

The report was signed on behalf of LakeShore Biopharma Co., Ltd. by Rachel Yu, who serves as a Director and the company’s Chief Financial Officer, indicating executive-level oversight of the disclosure and related exhibit.

When was LakeShore Biopharma’s (YSBPW) Form 6-K dated?

The Form 6-K is dated September 10, 2025. This date indicates when LakeShore Biopharma formally authorized and submitted the report covering the press release about its special committee’s appointment of external financial and legal advisors.

What type of SEC annual report does LakeShore Biopharma (YSBPW) indicate it uses?

LakeShore Biopharma indicates that it files annual reports on Form 20-F, which is the standard SEC annual reporting format for foreign private issuers listing detailed financial and operational information for investors.